ABA (²¹²Pb-undisclosed)
Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
Non-ClinicalIn development
Key Facts
Indication
Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
Phase
Non-Clinical
Status
In development
Company
About ARTBIO
ARTBIO is pioneering a holistic approach to Alpha Radioligand Therapy (ART), combining a differentiated pipeline with proprietary isotope production and manufacturing capabilities. Founded in 2021 by the inventors of the first-ever metabolically targeted alpha therapy (Xofigo), the company is advancing multiple programs, with its lead candidate AB001 now in Phase 1/2 clinical trials for prostate cancer. Backed by a strong syndicate of top-tier life science investors, ARTBIO aims to unlock the superior efficacy and safety profile of alpha-emitting radioligands to treat a range of solid tumors.
View full company profile